Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

MADRIGAL PHARMACEUTICALS, INC. (MDGL)

As of 2026-11-20 · 12/15 boxes filled from SEC filings and market data

Report price $379.10 (close 2026-11-20)

Conclusion: PASS

Conviction low · base case none · downside -29% · upside +23%

At $379.10 the market pays 5.73x TTM EV/Sales for $1.43B of revenue with -$152.7M TTM EBIT and -$168.7M of free cash flow, and it prices +5.9% annual revenue growth for ten years. No comparable peer multiple sets a base case, so the call rests on the two cases alone. PASS here means 'not a value buy at this price', not a bad business: a growth compounder judged on a deep-value checklist, with ROIC of -804.0% against a 7.0% WACC and an FCF yield of -1.9% leaving too little edge. The downside is -29.2% to $268.30, on -10.0% sales at a compressed EV/Sales of 4.37x (today 5.73x). The upside is +23.2% to $467.21, on +25% sales at today's EV/Sales of 5.73x. There is no base case: no independent multiple from the peer median or the company's own history was available, and a base at today's multiple is today's price by construction. Paulson & Co. at 25.8% of its 13F book and Baker Bros at 5.2% hold against this, but quarter-end marks filed up to 45 days later do not change the arithmetic the price sets.

Key numbers

  • Share price: $379.10
  • Market cap: $8.81B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $1.43B
  • FCF yield: -1.9%
  • Price / book: 14.05x
  • Revenue growth (latest fiscal year): +432.1%
  • ROIC (TTM): -804.0%
  • WACC: 7.0%
  • Economic profit spread: -811.0 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    Madrigal, which filed earlier as Synta Pharmaceuticals Corp until 2016-08-01, is a commercial-stage biopharma whose revenue comes from Rezdiffra, its only approved product: FY2025 revenue was $958.4M and TTM to Sep 2026 was $1.43B, up from $0 in FY2022 and FY2023. The FY2020 filing shows a clinical-stage company with resmetirom in Phase 3 and no approved product; by FY2025 it had FDA accelerated approval and an EC conditional marketing authorization, plus a licensed pipeline. It remains loss-making on operating income, net income and operating cash flow in FY2025 and TTM to Sep 2026.

  2. ✓ 2. Competitive advantage

    The advantage is a first-mover regulatory position, not cost, scale or switching costs: Rezdiffra was the first drug approved by both the FDA and the EC for MASH with moderate-to-advanced fibrosis (FDA March 2024, EC CMA August 2025), but Novo's semaglutide is now FDA-approved in MASH and more than 140 MASH programs are in development. The company owns no manufacturing plants and buys all supply from CMOs, so there is no scale-cost moat. The record shows revenue scaling fast ($180.1M FY2024 to $958.4M FY2025 to $1.43B TTM to Sep 2026) while operating income stayed negative (-$300.1M FY2025, -$152.7M TTM), so no margin or return advantage has yet been demonstrated. Durability is conditional: US approval is accelerated and EU approval a CMA, both dependent on confirmatory outcomes trials, and payors/PBMs can steer patients to alternatives.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 product revenue was $431.3 million, up 50% from $287.3 million in Q3 2025, and the quarter produced operating income of $56.0 million and net income of $55.4 million, which the company calls its first profitable quarter. The nine-month picture is still a net loss of $96.9 million on $1,106.9 million of revenue, with SG&A up 44% and cost of sales including a $10.4 million inventory write-down. Cash was $961.8 million at Sep 30, 2026, debt principal was $350.0 million, and the disclosed outlook is trial timing rather than numeric financial guidance.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans